BC Innovations | Nov 20, 2014
Cover Story

Tapping TOPK

Although targeting proteins involved in cell division is falling out of fashion in cancer research because of the difficulty of distinguishing between diseased and normal cells, several companies are still exploring enzymes that could be...
BioCentury | May 14, 2012

Vertex the odds-on favorite

Investors think there's still room to run for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which saw its valuation more than double last week on positive Phase II data for a drug combination that could treat nearly half...
BioCentury | Nov 7, 2011

Clovis closes in

Clovis closes in Clovis Oncology Inc. is aiming for the largest IPO by a therapeutics company since the $215.6 million debut for gastrointestinal play Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in February 2010. Clovis began its road...
Items per page:
1 - 3 of 3